J&J CEO Says Curing Some Cancers Within a Decade Is Realistic

Johnson & Johnson CEO Joaquin Duato said on June 10, 2026, that curing certain cancers and transforming others into chronic manageable diseases is a scientifically realistic goal within the next decade. The statement carries weight: J&J's oncology pipeline targets multiple myeloma and lung cancer with bispecific antibodies and CAR-T therapies achieving deep response rates. Duato's dual framing—cure versus chronification—reflects clinical precision. Whether deep clinical data supports decade-horizon claims remains unclear.